Safety Profile
Known Safety Concerns
- At typical capsule doses (1-10 mg) essentially inert
- Unsubstantiated internet claims of immune suppression are not evidence-based
- At very high doses may theoretically reduce nutrient absorption (not clinically relevant)
- Porcine or bovine stearic acid sources may concern religious or vegan consumers
Contraindications
- At typical capsule doses (1-10 mg) essentially inert
- Unsubstantiated internet claims of immune suppression are not evidence-based
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Magnesium stearate is a flow agent and anti-caking excipient in up to 90% of all tablets and capsules. Claims that magnesium stearate suppresses the immune system or creates a biofilm in the gut are not supported by evidence. At supplement doses (typically 1-10 mg per capsule) it is inert. At extremely high experimental doses it may reduce drug absorption, but this is not clinically relevant at typical supplement use.
Biological and Chemical Classification
- Scientific Name
- Magnesium octadecanoate
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Excipient
- Evidence consistency: High consistency across studies (100%)
- At typical capsule doses (1-10 mg) essentially inert
- Unsubstantiated internet claims of immune suppression are not evidence-based
- At very high doses may theoretically reduce nutrient absorption (not clinically relevant)
- Porcine or bovine stearic acid sources may concern religious or vegan consumers
The available scientific evidence for Magnesium Stearate indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 24 მარ 2026, 09:20
Evidence Distribution
-
Observational / other LOW evidence YELLOWComparing the Effect of Drug, Sodium Carboxymethyl Cellulose and Other Excipients on Shape, Size and Drug Release from the Matrices. ↗Alhmoud H et al.. Comparing the Effect of Drug, Sodium Carboxymethyl Cellulose and Other Excipients on Shape, Size and Drug Release from the Matrices.. Int J Pharm Compd. 2026. PMID:41819133.PMID 41819133 ↗Journal Int J Pharm CompdYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41819133/
-
Observational / other LOW evidence YELLOWMoisture-Proof Herbal Extract Pellets Prepared via Asymmetric Liquid Layering Technology Combined with Mesoporous Silica and Magnesium Stearate. ↗Ma S et al.. Moisture-Proof Herbal Extract Pellets Prepared via Asymmetric Liquid Layering Technology Combined with Mesoporous Silica and Magnesium Stearate.. AAPS PharmSciTech. 2026. PMID:41807885.PMID 41807885 ↗Journal AAPS PharmSciTechYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41807885/
-
Observational / other LOW evidence YELLOWAcoustic Monitoring of Lubrication and Compaction Effects on Tablet Performance Using Broadband Acoustic Resonance Dissolution Spectroscopy. ↗Peddapatla RVG et al.. Acoustic Monitoring of Lubrication and Compaction Effects on Tablet Performance Using Broadband Acoustic Resonance Dissolution Spectroscopy.. Mol Pharm. 2026. PMID:41797342.PMID 41797342 ↗Journal Mol PharmYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41797342/
-
Observational / other LOW evidence YELLOWAlpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty: A Case Report. ↗Kohli-Pamnani A et al.. Alpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty: A Case Report.. JBJS Case Connect. 2026. PMID:41785334.PMID 41785334 ↗Journal JBJS Case ConnectYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41785334/
-
Observational / other LOW evidence YELLOWLiquisolids as a platform for the formulation of cannabis tablets. ↗Appelhaus J et al.. Liquisolids as a platform for the formulation of cannabis tablets.. Int J Pharm X. 2026. PMID:41783644.PMID 41783644 ↗Journal Int J Pharm XYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41783644/
-
Observational / other LOW evidence YELLOWSingle vs Dual Lactose-Polyethylene Glycol 3000 Microcarrier Systems for Pulmonary Salmeterol and Fluticasone Targeted Delivery. ↗Akram MW et al.. Single vs Dual Lactose-Polyethylene Glycol 3000 Microcarrier Systems for Pulmonary Salmeterol and Fluticasone Targeted Delivery.. Drug Des Devel Ther. 2026. PMID:41778147.PMID 41778147 ↗Journal Drug Des Devel TherYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41778147/
-
Observational / other LOW evidence YELLOWUnderstanding real-time water penetration dynamics in tablets using synchrotron X-ray micro-computed tomography. ↗Kalugin D et al.. Understanding real-time water penetration dynamics in tablets using synchrotron X-ray micro-computed tomography.. J Pharm Sci. 2026. PMID:41759974.PMID 41759974 ↗Journal J Pharm SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41759974/
-
Observational / other LOW evidence YELLOWPhysicochemical characterization and clinical evaluation of 3D-printed subdivided tablets of 6-Mercaptopurine with broad dosage variations. ↗Liu J et al.. Physicochemical characterization and clinical evaluation of 3D-printed subdivided tablets of 6-Mercaptopurine with broad dosage variations.. Int J Pharm. 2026. PMID:41644072.PMID 41644072 ↗Journal Int J PharmYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41644072/
-
Observational / other LOW evidence YELLOWScoping review to identify data needs and environmental hotspots for future LCA Studies: Insights into pharmaceutical excipients and processes. ↗Autzen Virtanen A et al.. Scoping review to identify data needs and environmental hotspots for future LCA Studies: Insights into pharmaceutical excipients and processes.. Eur J Pharm Sci. 2026. PMID:41611099.PMID 41611099 ↗Journal Eur J Pharm SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41611099/
-
Observational / other LOW evidence YELLOWPharmaceutical development of tablets based on cryolyophilized porcine skin. ↗Panysheva O. Pharmaceutical development of tablets based on cryolyophilized porcine skin.. Pharm Sci Adv. 2025. PMID:41550663.PMID 41550663 ↗Journal Pharm Sci AdvYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41550663/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Magnesium Stearate. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Magnesium Stearate
A score of 1.5 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.